Literature DB >> 6813467

IV N-acetylcysteine treatment of hematologic reactions to chrysotherapy.

N F Godfrey, A Peter, T M Simon, A Lorber.   

Abstract

Twelve patients with adverse hematologic reactions to chrysotherapy received intravenous N-acetylcysteine (IV NAC) to achieve removal and/or redistribution of gold. Urine gold excretion while on IV NAC doubled that predicted from control measurements. Treatment within 20 days of the last gold injection was associated with better recovery of hematologic parameters. No untoward reactions from IV NAC were encountered. The pathogenesis of gold induced hematologic reactions is examined from both toxic as well as immunological perspectives.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813467

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Adverse reactions with oral and parenteral gold preparations.

Authors:  E C Tozman; N L Gottlieb
Journal:  Med Toxicol       Date:  1987 May-Jun

2.  Gold-induced aplastic pancytopenia: 14-month survival through multiple transfusions.

Authors:  R Reychler; T De Geeter; L A Verbruggen
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

Review 3.  Utility of acetylcysteine in treating poisonings and adverse drug reactions.

Authors:  P A Chyka; A Y Butler; B J Holliman; M I Herman
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

4.  Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally?

Authors:  E Hjortsø; J S Fomsgaard; N Fogh-Andersen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Differential effect of N-acetylcysteine on excretion of the metals Hg, Cd, Pb and Au.

Authors:  H Ottenwälder; P Simon
Journal:  Arch Toxicol       Date:  1987-07       Impact factor: 5.153

6.  N-acetylcysteine as an antidote in methylmercury poisoning.

Authors:  N Ballatori; M W Lieberman; W Wang
Journal:  Environ Health Perspect       Date:  1998-05       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.